CDD-2103

**CDD-2103** is an investigational standardized Chinese herbal medicine comprising nine herbal ingredients, also referred to as modified Zhenwu decoction. Developed by Hong Kong Baptist University and its Centre for Chinese Herbal Medicine Drug Development, it is being evaluated primarily for maintenance of remission in ulcerative colitis, particularly in patients with the traditional Chinese medicine pattern of spleen deficiency with dampness accumulation. Preclinical colitis studies indicate that the formulation promotes an intestinal tolerogenic immune environment, including tolerogenic dendritic-cell-mediated regulatory T-cell differentiation, reduced inflammatory macrophage abundance, and improved epithelial barrier integrity through soluble guanylate cyclase-mediated cyclic guanosine monophosphate and protein kinase G signaling. CDD-2103 received National Medical Products Administration authorization for a clinical trial in China in August 2024; it is also planned for evaluation in diarrhea-predominant irritable bowel syndrome.

Other names

MZWDModified Zhenwu Decoction